Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3884-3894

  Olson, Jon A ^a   George, Ancy ^a   Constable, David ^a   Smith, Peter ^a   Proffitt, Richard T ^b   Adler Moore, Jill P ^a  

^a CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^b RichPro Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; FEMALE; FUNGUS CULTURE; KIDNEY; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SPLEEN; SURVIVAL RATE; SWISS WEBSTER MOUSE;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; ECHINOCANDINS; FEMALE; MICE; MICROBIAL SENSITIVITY TESTS; PULMONARY ASPERGILLOSIS;

EID: 77956109969     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01554-09     Document Type: Article

References (62)

1. Adler-Moore, J., and R. T. Proffitt. 2002. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 49(Suppl. A):21-30.
2. Adler-Moore, J. P., and R. T. Proffitt. 2008. Amphotericin B lipid preparations: what are the differences? Clin. Microb. Infect. 14(Suppl. 4):25-36.
3. Aliff, T. B., P. G. Maslak, J. G. Jurcic, M. L. Heaney, K. N. Cathcart, K. A. Sepkowitz, and M. A. Weiss. 2003. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97:1025-1032.
4. Antachopoulos, C., J. Meletiadis, T. Sein, E. Roilides, and T. J. Walsh. 2008. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob. Agents Chemother. 52:321-328.
5. Barwicz, J., and P. Tancrède. 1997. The effect of aggregation state on amphotericin-B on its interactions with cholesterol- or ergosterol-containing phosphatidylcholine monolayers. Chem. Phys. Lipids 85:145-155.
6. Bowman, J. C., P. S. Hicks, M. B. Kurtz, H. Rosen, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2002. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46:3001-3012.
7. Bretagne, S., A. Marmorat-Khuong, M. Kuentz, J. P. Latgé, E. Bart- Delabesse, and C. Cordonnier. 1997. Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients. J. Infect. 35:7-15. (Pubitemid 27380030)
8. Caillot, D., A. Thiébaut, R. Herbrecht, S. de Botton, A. Pigneux, F. Bernard, J. Larché, F. Monchecourt, S. Alfandari, and L. Mahi. 2007. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 110:2740-2746. (Pubitemid 350250344)
9. Cesaro, S., T. Toffolutti, C. Messina, E. Calore, R. Alaggio, R. Cusinato, M. Pillon, and L. Zanesco. 2004. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur. J. Haematol. 73:50-55.
10. Clemons, K. V., and D. A. Stevens. 2006. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med. Mycol. 44:69-73.
11. Clemons, K. V., and D. A. Stevens. 2004. Comparative efficacies of four amphotericin B formulations - Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet - against systemic murine aspergillosis. Antimicrob. Agents Chemother. 48:1047-1050.
12. Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2005. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. 49:4867-4875.
13. Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50:1293-1297.
14. Cornely, O. A., J. Maertens, M. Bresnik, R. Ebrahimi, A. J. Ullmann, E. Bouza, C. P. Heussel, O. Lortholary, C. Rieger, A. Boehme, M. Aoun, H. A. Horst, A. Thiebaut, M. Ruhnke, D. Reichert, N. Vianelli, S. W. Krause, E. Olavarria, R. Herbrecht, and the AmBiLoad Trial Study Group. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin. Infect. Dis. 44:1289-1297.
15. Czub, J., and M. Baginski. 2006. Modulation of amphotericin B membrane interaction by cholesterol and ergosterol - a molecular dynamics study. J. Phys. Chem. 110:16743-16753.
16. Denning, D. W. 1996. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23:608-615.
17. -/- mouse model of chronic granulomatous disease. Antimicrob. Agents Chemother. 50:422-427.
18. Douglas, C. M. 2001. Fungal β(1, 3)-D-glucan synthesis. Med. Mycol. 39(Suppl. 1):55-66.
19. Enoch, D. A., H. A. Ludlam, and N. M. Brown. 2006. Invasive fungal infections: a review of epidemiology and management options. J. Med. Microb. 55:809-818.
20. Ghannoum, M., and L. B. Rice. 1999. Antifungal agents: mode of action, mechanism of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microb. Rev. 12:501-517.
21. Graybill, J. R., R. Bocanegra, G. M. Gonzalez, and L. K. Najvar. 2003. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J. Antimicrob. Chemother. 52:656-662.
22. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, B. de Pauw, and the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
23. Ibrahim, A. S., J. C. Bowman, V. Avanessian, K. Brown, B. Spellberg, J. E. Edwards, Jr., and C. M. Douglas. 2005. Caspofungin inhibits Rhizopus oryzae 1,3-β-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low, but not a high dose, during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49:721-727.
24. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
25. Kartsonis, N. A., A. J. Saah, C. Joy Lipka, A. F. Taylor, and C. A. Sable. 2005. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J. Infect. 50:196-205.
26. Kriván, G., J. Sinkó, I. Z. Nagy, V. Goda, P. Reményi, A. Bátai, S. Lueff, B. Kapás, M. Réti, A. Tremmel, and T. Masszi. 2006. Successful combined antifungal salvage therapy with liposomal amphothericin B and caspofungin for invasive Aspergillus flavus infection in a child following allogeneic bone marrow transplantation. Acta Biomed. 77(Suppl. 2):17-21.
27. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
28. Lanternier, F., and O. Lortholary. 2008. Liposomal amphotericin B: what is its role in 2008? Clin. Microbiol. Infect. 14(Suppl. 4):71-83.
29. Lass-Flörl, C., M. Nagl, E. Gunsilius, C. Speth, H. Ulmer, and R. Würzner. 2002. In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against Aspergillus conidia and hyphae. Mycoses 45:166-169.
30. Lass-Flörl, C., A. Mayr, S. Perkhofer, G. Hinterberger, J. Hausdorfer, C. Speth, and M. Fille. 2008. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 52:3637-3641.
31. Lee, J. W., M. A. Amantea, P. A. Francis, E. E. Navarro, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1994. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. 38:713-718.
32. Leenders, A. C., S. Daenen, R. L. Jansen, W. C. Hop, B. Lowenberg, P. W. Wijermans, J. Cornelissen, R. Herbrecht, H. van der Lelie, H. C. Hoogst- eden, H. A. Verbrugh, and S. de Marie. 1998. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br. J. Haematol. 103:205-212.
33. Leenders, A. C. A. P., S. de Marie, M. T. ten Kate, I. A. Bakker-Woudenberg, and H. A. Verbrugh. 1996. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. J. Antimicrob. Chemother. 38:215-225.
34. Lin, S.-J., J. Schranz, and S. M. Teutsch. 2001. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32:258-366.
35. Maertens, J., J. Verhaegen, K. Lagrou, J. Van Eldere, and M. Boogaerts. 2001. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97:1604-1610. (Pubitemid 32217224)
36. Marr, K. A., R. A. Carter, F. Crippa, A. Wald, and L. Corey. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34:909-917.
37. Martín-Mazuelos, E., J. Pemán, A. Valverde, M. Chaves, M. C. Serrano, and E. Cantón. 2003. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J. Antimicrob. Chemother. 52:365-370.
38. Olson, J. A., J. P. Adler-Moore, G. M. Jensen, J. Schwartz, M. C. Dignani, and R. T. Proffitt. 2008. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob. Agents Chemother. 52:259-268.
39. Olson, J. A., J. P. Adler-Moore, J. Schwartz, G. M. Jensen, and R. T. Proffitt. 2006. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob. Agents Chemother. 50:2122-2131.
40. Olson, J. A., J. P. Adler-Moore, P. J. Smith, and R. T. Proffitt. 2005. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob. Agents Chemother. 49:4895-4902.
41. Olson, J. A., D. S. Constable, P. J. Smith, and J. P. Adler-Moore. 2006. Abstr. 46th Annu. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, poster M-1746. American Society for Microbiology, Washington, DC.
42. Pancham, S., C. Hemmaway, H. New, E. Albert, I. Dokal, I. A. Roberts, and M. McCloy. 2005. Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation. Pediatr. Transplant. 9:254-257.
43. Perfect, J. R., G. M. Cox, J. Y. Lee, C. A. Kauffman, L. de Repentigny, S. W. Chapman, V. A. Morrison, P. Pappas, J. W. Hiemenz, D. A. Stevens, and the Mycoses Study Group. 2001. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin. Infect. Dis. 33:1824-1833.
44. Pfaller, M. A., P. G. Pappas, and J. R. Wingard. 2006. Invasive fungal pathogens: current epidemiological trends. Clin. Infect. Dis. 43(Suppl. 1): S3-S14.
45. Richardson, M., and C. Lass-Flörl. 2008. Changing epidemiology of systemic fungal infections. Clin. Microbiol. Infect. 14(Suppl. 4):5-24.
46. Shao, P.-L., L.-M. Huang, and P.-R. Hsueh. 2007. Recent advances and challenges in the treatment of invasive fungal infections. Int. J. Antimicrob. Agents 30:487-495.
47. Sionov, E., S. Mendlovic, and E. Segal. 2006. Efficacy of amphotereicin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J. Infect. 53:131-139. (Pubitemid 44028669)
48. Sionov, E., S. Mendlovic, and E. Segal. 2005. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and GCSF. J. Antimicrob. Chemother. 56:594-597.
49. Smith, P. J., J. A. Olson, D. Constable, J. Schwartz, R. T. Proffitt, and J. P. Adler-Moore. 2007. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J. Antimicrob. Chemother. 59:941-951.
50. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
51. Takemoto, K., Y. Yamamoto, Y. Ueda, Y. Sumita, K. Yoshida, and Y. Niki. 2004. Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J. Antimicrob. Chemother. 53:311-317.
52. Torrado, J. J., R. Espada, M. P. Ballesteros, and S. Torrado-Santiago. 2008. Amphotericin B formulations and drug targeting. J. Pharm. Sci. 97:2405-2425.
53. Vallor, A. C., W. R. Kirkpatrick, L. K. Najvar, R. Bocanegra, M. C. Kinney, A. W. Fothergill, M. L. Herrera, B. L. Wickes, J. R. Graybill, and T. F. Patterson. 2008. Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob. Agents Chemother. 52:2593-2598.
54. Viscoli, C., R. Herbrecht, H. Akan, I. Baila, C. Doyen, A. Gallamini, A. Giagounidis, O. Marchetti, R. Martino, L. Meerts, W. Paesmans, M. R. Shivaprakash, A. J. Ullmann, J. Maertens, and the Infectious Diseases Group of the EORTC. 2007. Caspofungin © as first-line therapy of invasive aspergillosis (IA) in haematological patients (pts): a study of the EORTC Infectious Disease Group, abstr. O12. J. Chemother. 19(Suppl. 3):36.
55. von Eiff, M., N. Roos, R. Schulten, M. Hesse, M. Zühlsdorf, and J. van de Loo. 1995. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 62:341-347.
56. Walsh, T. J., V. Yeldandi, M. McEvoy, C. Gonzalez, S. J. Chanock, A. Freifeld, N. I. Seibel, P. Jarosinski, G. Boswell, I. Bekersky, A. Alak, D. Buell, J. Barret, and W. Wilson. 1998. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 42:2391-2398.
57. Walsh, T. J., J. L. Goodman, P. Pappas, I. Bekersky, D. N. Buell, M. Roden, J. Barrett, and E. J. Anaissie. 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45:3487-3496.
58. Warn, P. A., G. Morrissey, J. Morrissey, and D. W. Denning. 2003. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J. Antimicrob. Chemother. 51:913-919.
59. Wasan, K. M., O. Sivak, M. Rosland, V. Risovic, and K. Bartlett. 2007. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet® and AmBisome® in combination with Caspofungin to rats infected with Aspergillus fumigatus. J. Pharm. Sci. 96:1737-1747.
60. Watabe, E., T. Nakai, S. Matsumoto, F. Ikeda, and K. Hatano. 2003. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob. Agents Chemother. 47:1995-1998.
61. Wiederhold, N. P., D. P. Kontoyiannis, C. Jingduan, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration- dependent activity. J. Infect. Dis. 190:1464-1471.
62. Wiederhold, N. P. 2009. Paradoxical echinocandin activity: a limited in vitro phenomenon? Med. Mycol. 47(Suppl. 1):S369-S375.